Our in-house capabilities: High-performance manufacturing of finished dosage forms
Driving efficiency is our key. Highest quality while maintaining the most efficient us of time
From the inital product to the final production via our own manufacturing facilities – this enables faster timelines and simpler coordination. From small batch to high volume production: Get a reliable and flexible supply of high-quality pharmaceuticals for a global market access.
As fully integrated pharmaceutical company, we offer our clients a competitive supply chain management to ensure on-time delivery. We drive efficiency by keeping our supply chains simple and reaching economies of scales in our own manufacturing sites. Modern supply chain solutions and a lean management approach ensure that our products reach the right place in the right condition and quantity at the best price on time. Our two manufacturing sites in Europe and India as well as our global network of contract manufacturers allow us to manufacture nearly any kind of formulation and dosage form according to GMP standards. No matter if a controlled drug or a special dosage form (like patches or inhalers) – our about 60 years experience and our excellent know how in terms of regulatory and quality requirements guarantee the best possible supply chain. Both sites continuously expand in novel technologies, production capacities, equipment, and warehouse storage to drive efficiency and to meet the growing demand of our customers and better healthcare. With our new high potent manufacturing block in India we are committed to drive for growth and innovation and are now able to manufacture a well-defined and specialized portfolio of highly potent drug formulations inhouse.
All our pharmaceutical production plants are equipped with most up-to-date technologies, highly qualified professionals and highest safety standards. This ensures full compliance with Good Manufacturing Practice (GMP). Apart from the most important governmental approvals, our sites are periodically inspected by leading pharmaceutical companies. Our high-performance manufacturing capabilities deliver drugs for patients worldwide. We succeed through our fully integrated facilities and a powerful production capability for high-quality pharmaceuticals.
Tiefenbacher manufacturing: Excellence beyond the manufacturing
State-of-the-art facilities for powerful drug production
We, at TIEFENBACHER GROUP, go beyond manufacturing with a commitment to quality, safety, and reliability that is anchored in everything we do. We plan the entire production processes earlier and more carefully, so that the value of the overall drug package can be maximized.
Our industry expertise and experiences allows us to manufacture a wide range of high-quality pharmaceuticals: generics, value added, and innovative drugs including high potent drugs for better healthcare worldwide.
efficiency driven supply chain management
>
own state-of-the-art production sites
>
small batch and high-volume-production
>
SPC waiver site in EU (Cyprus)
>
efficiency driven supply chain management
>
own state-of-the-art production sites
>
small batch and high-volume-production
>
SPC waiver site (DELORBIS)
>
up to 3 bn units p.y.production capacity
>
GMP compliance including FDA
>
Product safety & quality for high-quality FDF
>
Generic, value added and innovative drugs
>
up to 3 bn units p.y.production capacity
>
GMP compliance including FDA
>
Product safety & quality for high-quality FDF
>
Generic, value added and innovative drugs
>
European manufacturing site of TIEFENBACHER GROUP
High-volume production of high-quality pharmaceuticals made in Europe
We, at TIEFENBACHER GROUP, are continuously expanding in novel technologies and capabilities to accelerate development, improve quality, and boost productivity for better healthcare.
The manufacturing facilities of TIEFENBACHER GROUP on Cyprus have been designed to accommodate the bulk production as well as primary and secondary packaging operations of non-sterile oral solid dosage forms (tablets, capsules, and powder suspensions for reconstitution). The production and packaging lines are equipped with sophisticated technology from the first manufacturing step throughout to the last packaging step and are flexible to manage small batch as well as high volume productions. Thanks to our highly competent personnel as well as the state-of-the-art equipment available in the quality control laboratory we can also offer to our partners:
- EU batch testing and release of pharmaceutical products
- ICH stability studies at long-term, intermediate, and accelerated conditions for all zones (incl. zone IVb)
- many analytical laboratory services (e. g. chemical testing of raw materials and drug products, method validation/transfer, comparative dissolution profiles) and support from our experienced analysts
- technology transfer
- import/storage/warehousing
Indian, FDA approved manufacturing site of TIEFENBACHER GROUP
Own high-performance manufacturing site in India for better healthcare – including facility for highly potent drugs
Our manufacturing facility of excellence provides our customers with reliable products that include European (EMA) and US (FDA) approvals.
We combine the cost-efficiency of manufacturing sites in India with rigorous standards of Europe and USA. With TIEFENBACHER LABORATORIES, we own two state-of-the-art manufacturing sites located in Hyderabad, India for producing high-quality pharmaceuticals. Featuring a GMP compliant environment on a 32.000 m² sized plant, TIEFENBACHER LABORATORIES is equipped with the most modern technologies for manufacturing, testing, packing, warehousing, and releasing solid oral dosage forms. With our new high potent manufacturing block we are committed to drive for growth and innovation and are now able to produce a well-defined and specialized portfolio of highly potent drugs for the global market.
Quality control is an integral part of TIEFENBACHER LABORATORIES´ manufacturing process. The facility holds the ISO 14001:2014 and ISO 18001:2015 certifications and was successfully inspected by the German BGV, the US FDA authorities, the Russian MIT, and the Turkish Ministry of Health.